Education
About Us
Working with TipRanks
Follow Us
Helus Pharma (HELP)
NASDAQ:HELP
HELP Stock Chart & Stats
$4.81
-$0.06(-0.78%)
At close: 4:00 PM EST
$4.81
-$0.06(-0.78%)
Day’s Range― - ―
52-Week Range$4.52 - $9.83
Previous Close$7.77
Volume369.09K
Average Volume (3M)N/A
Market Cap
$1.39M
Enterprise Value$0.00
Total Cash (Recent Filing)$116.53M
Total Debt (Recent Filing)$40.19M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Jul 01, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding50,035,793
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio-16.39
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$47.80Price Target Upside893.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Helus Pharma News
HELP FAQ
What was Helus Pharma’s price range in the past 12 months?
Helus Pharma lowest stock price was $4.52 and its highest was $9.83 in the past 12 months.
What is Helus Pharma’s market cap?
Helus Pharma’s market cap is $1.39M.
When is Helus Pharma’s upcoming earnings report date?
Helus Pharma’s upcoming earnings report date is Jul 01, 2026 which is in 99 days.
How were Helus Pharma’s earnings last quarter?
Helus Pharma released its earnings results on Feb 13, 2026. The company reported -$0.991 earnings per share for the quarter, missing the consensus estimate of -$0.759 by -$0.232.
Is Helus Pharma overvalued?
According to Wall Street analysts Helus Pharma’s price is currently Undervalued.
Does Helus Pharma pay dividends?
Helus Pharma does not currently pay dividends.
What is Helus Pharma’s EPS estimate?
Helus Pharma’s EPS estimate is -0.79.
How many shares outstanding does Helus Pharma have?
Helus Pharma has 50,035,793 shares outstanding.
What happened to Helus Pharma’s price movement after its last earnings report?
Helus Pharma reported an EPS of -$0.991 in its last earnings report, missing expectations of -$0.759. Following the earnings report the stock price went up 2.872%.
Which hedge fund is a major shareholder of Helus Pharma?
Currently, no hedge funds are holding shares in HELP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helus Pharma
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
HELP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.View all HELP earnings summariesHELP Stock 12 Month Forecast
Average Price Target
$47.80
▲(893.76% Upside)
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
―
Mindbio Therapeutics Corp.
―
Ownership Overview
1.29% Insiders
―
Mutual Funds
43.57% Other Institutional Investors
54.76% Public Companies and Individual Investors
Options Prices
Currently, No data available
---